Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02082821 · ClinicalTrials.gov registry record

A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy

A clinical trial of Cardiac Allograft Vasculopathy, sponsored by Boston Children's Hospital.

Completed
Registry status
200
Enrollment target
1
Study location

NCT02082821 is a study of Cardiac Allograft Vasculopathy that has completed, run by Boston Children's Hospital. The registered enrollment target is 200 participants, above the 64-participant average among 3 other Cardiac Allograft Vasculopathy trials with a reported enrollment target (213% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02082821, a study of Cardiac Allograft Vasculopathy, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

Heart transplantation (HT) is a lifesaving procedure for patients with end-stage heart failure and provides a better survival and quality of life if compared to medical treatment. HT is subject to alloimmune response, which, if left uncontrolled, is capable of jeopardizing long-term cardiac function. Advances in immunosuppression have enhanced the survival of HT patients. Nearly 2500 HT per year have been performed in the US during the last 10 years and despite significant improvements, long-term survival rates remain poor. More than 20% of patients do not survive more than 3 years, and those who survive are afflicted by long-term complications of alloimmunity and chronic immunosuppression. Life expectancy of patients who lose cardiac allografts is dramatically poor due to the absence of any therapeutic tool apart from re-transplantation, which is plagued by poor outcomes. The identification of novel therapeutic targets is thus mandatory. ATP/P2X7R signaling in T cells is highly relevant for cardiac allograft survival. ATP is a small molecule present at high concentrations inside cells; it is released as extracellular ATP (eATP) following cell damage or death where it acts as a danger signal. ATP is sensed by the P2X receptors (seven receptors named P2X1-7), mainly expressed by T lymphocytes. We have recently demonstrated that the ATP/P2X7R axis has a key role in cardiac allograft survival in humans and mice. Cardiac allograft vasculopathy (CAV) is a major limiting factor for HT survival; indeed CAV occurs in 50% of HT recipients by 5 years after transplantation and invariably results in allograft failure. CAV is clearly of immunological origin, as syngeneic murine grafts do not develop it. Once CAV occurs, the most definitive treatment is re-transplantation, but survival remains poor. We hypothesize that a single nucleotide polymorphysm (SNP) loss-of-function P2X7R mutation (p.Glu496Ala / c.1513A\>C, rs3751143) generates a compensatory upregulation of the other pur

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2014-01
Est. Completion 2020-12

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT02082821

The ClinicalTrials.gov registry entry for NCT02082821 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 64-participant average among 3 other Cardiac Allograft Vasculopathy trials with a reported enrollment target (213% higher). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiac Allograft Vasculopathy appearing as the primary indexed condition, and to 0 interventions.

NCT02082821 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02082821 about?

NCT02082821 is a clinical study titled "A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy". Heart transplantation (HT) is a lifesaving procedure for patients with end-stage heart failure and provides a better survival and quality of life if compared to medical treatment. HT is subject to alloimmune response, which, if left uncontrolled, is capable of jeopardizing long-term cardiac function...

What is the current status of trial NCT02082821?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-01. Estimated completion is 2020-12.

What conditions does trial NCT02082821 study?

This clinical trial studies the following conditions: Cardiac Allograft Vasculopathy.

Who is sponsoring clinical trial NCT02082821?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02082821 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiac Allograft Vasculopathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.